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Edited by Hans-Dieter KlenkAbstract Retroviral infection triggers the cytoplasmic translo-
cation of two Crm1-dependent shuttle factors, namely the Ini1
(integrase interactor 1, hSNF5) and the promyelocytic leukemia
(PML) protein. Blocking nuclear export of shuttle factors by
leptomycin B increases the eﬃciency of retroviral integration,
suggesting that some may mediate antiviral activity. While
PML was shown to counteract proviral establishment, it re-
mained unclear whether Ini1, a protein implicated in various pro-
cesses during human immunodeﬁciency virus replication, has the
same potential. Employing RNA interference-mediated knock-
down of Ini1, we show here that the simultaneous accumulation
of both proteins in the cytoplasm likely reﬂects two non-interde-
pendent phenomena. Furthermore, Ini1 does not interfere with
retroviral integration, as cells lacking Ini1 show no increased
infection susceptibility.
 2004 Published by Elsevier B.V. on behalf of the Federation of
European Biochemical Societies.
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Leptomycin B (LMB) is a speciﬁc inhibitor of the Crm1/
exportin1 protein and LMB-treatment of cells results in the
nuclear accumulation of Crm1/exportin1-dependent cargo fac-
tors (reviewed in [1]). Retroviral infection implies trans-cyto-
plasmic migration and nuclear import of the viral genome
and associated proteins. Surprisingly, LMB treatment at least
doubles the number of cells infected with a lentiviral gene-
transfer vector (our unpublished observation and [2]). This ef-
fect suggests that Crm1-dependent shuttle factors mediate aAbbreviations: dsRNA, double-stranded RNA; EGFP, enhanced green
ﬂuorescence protein; FACS, ﬂuorescence activated cell sorting; HIV,
human immunodeﬁciency virus; Ini1, integrase interactor 1; LMB,
leptomycin B; PBS, phosphate-buﬀered saline; PI, propidium iodide;
PIC, preintegration complex; PML, promyelocytic leukemia protein;
POD, PML oncogenic domain; RNAi, RNA interference; siRNA,
small inhibitory RNA; VSV-G, vesicular stomatitis virus glycoprotein;
wt, wild type
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blocked in the presence of LMB. Interestingly, it was shown
recently that two Crm1-dependent shuttle factors are exported
to the cytoplasm shortly after infection with HIV-1: promyelo-
cytic leukemia (PML) protein and integrase interactor 1 (Ini1)
[2].
PML, ﬁrst described because of its involvement in acute pro-
myelocytic leukemia, is the organizing component of distinct
intra-nuclear substructures known as promyelocytic oncogenic
domains (PODs) [3,4]. A large number of alternatively spliced
transcripts are synthesized from the PML gene, resulting in a
variety of PML isoforms ranging in molecular weight from
48 to 97 kDa [5]. PML and PODs are involved in a variety
of cellular processes, including gene expression, cell cycle and
growth regulation, diﬀerentiation, and apoptosis [6]. While
usually 10–30 PODs are present per nucleus, this speckled pat-
tern is disrupted in cells either completely lacking PML or
expressing a PML fusion protein arising from a chromosomal
translocation [4,7–9]. Furthermore, a variety of viruses have
been shown to interact with PODs and/or to modify their
sub-nuclear distribution or their composition, amongst them
is the human immunodeﬁciency virus 1 (HIV-1) [2,10].
Shortly after HIV-1 infection, PML translocates from the
nucleus to the cytoplasm where the protein colocalizes with
incoming viral preintegration complexes (PICs). This Crm1-
mediated redistribution is independent of the presence of pack-
aged viral RNA genomes, accessory gene products and the
envelope protein used [2]. Treatment of cells with As2O3, a
drug that induces the recruitment of nucleoplasmic PML into
PODs and its degradation [11], rendered cells more susceptible
to HIV-1 infection, a phenomenon that was counteracted by
overexpression of PML. These observations suggest that cyto-
plasmic recruitment of PML may be part of an antiviral re-
sponse against HIV-1 infection [2]. This conclusion was,
however, subsequently challenged by the demonstration that
As2O3 largely released the Ref1-dependent block to reverse
transcription of N-tropic murine leukemia virus (MLV) and
enhanced infectivity of vesicular stomatitis virus glycoprotein
(VSV-G) pseudotyped HIV-based vectors in murine embry-
onic ﬁbroblasts (MEFs) from PML/ and wild type (wt) mice
at comparable levels [12]. Since As2O3 may also trigger apop-
tosis by disruption of the mitochondrial transmembrane po-
tential, it was hypothesized that eﬀects on mitochondria may
account for its stimulatory eﬀects on retroviral reverse trans-
ription. Interestingly, arsenic trioxide may also mediate the
speciﬁc degradation or deregulation of human TRIM5a, a
Ref1 and Lv1 retroviral restriction factor that, like PML,ation of European Biochemical Societies.
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RBCC/TRIM motif [5,13,14]. So far, it remains unclear if
these observations denote independent phenomena or if they
can be reconciled.
Turelli et al. [2] also demonstrated that the human SWI/
SNF-complex component Ini1 (or hSNF5) is exported jointly
with PML. Ini1 is a cellular binding partner of the HIV-1
integrase and was hypothesized to be implicated in targeting
HIV-1 PICs to favorable genomic sites [15]. Such an activity
may be important in view of the fact that HIV-1 integrates
preferentially into active genes [16]. The cytoplasmic delocal-
ization of Ini1 seems not to depend on functional PML, as it
also occurs after As2O3 treatment. Yet, it remains possible that
Ini1, in turn, mediates the export of PML. The experimental
proof of this hypothesis was hampered by the fact that PML
is already mislocalized in Ini1-deﬁcient cell lines [2]. Further-
more, it was not examined whether Ini1 may be implicated
in an antiviral response mechanism, like it is suggested for
PML. To improve and extend our understanding of cytoplas-
mic routing and fate of HIV-1 PICs, we sought to examine the
eﬀect of Ini1 knock-down during retroviral infection on the
subcellular localization of PML and on the eﬃciency of retro-
viral integration.2. Materials and methods
2.1. Plasmid construction
The vector pTRIP-LTR-EGFP is a derivative of the vector pTRIP-
EF1a [17], an HIV-based gene-transfer vector that comprises two
HIV-1 LTRs, the central triplex structure and a packaging signal,
yet has no coding capacity for HIV proteins and solely expresses en-
hanced green ﬂourescence protein (EGFP) from an internal EF1a pro-
moter. pTRIP-LTR-EGFP lacks, however, the EF1a promoter and
EGFP expression is consequently driven by the LTR. It was cloned
in two steps: ﬁrst, the vector pTRIP-PL was created by removal of
the EF1a-promoter/EGFP cassette from pTRIP-EF1a via MluI and
XhoI digestion and subsequent ligation of the annealed oligonucleo-
tides 5 0CGCGTCAGGATCC3 0 and 5 0TCGAGGATCCTGA3 0 into
the linearized vector, creating a new BamHI site between the MluI
and XhoI sites. Trip-PL was cut by BamHI and XhoI and the Bam-
HI/XhoI-fragment from pTRIP-EF1a (see above) comprising the
EGFP gene was inserted, giving rise to the pTRIP-LTR-EGFP vector.
2.2. Cell culture, immunoﬂuorescence and Western blotting
Cells were cultured in DMEM supplemented with 10% foetal calf
serum and Penicillin [50 U/ml]/Streptomycin [50 lg/ml] (Gibco). For
immunoﬂuorescence, HeLa cells (American Type Culture Collection,
CCL-2) were ﬁxed in 3% paraformaldehyde, permeabilized in Triton
X-100 (0.5% in phosphate-buﬀered saline, PBS) and stained subse-
quently with a polyclonal rabbit antiserum against PML [18] in a
1:200 dilution in PBS. Hoechst 33258 (Sigma) was used to visualize
the nuclear compartment. Immunoﬂuorescence analysis was per-
formed using a DMRX4 ﬂuorescence microscope with ﬁlters A and
TX2 (Leica) and images were taken with a Hamamatsu ORCAII-ER
cooled CCD-camera and processed with Openlab software (Improvi-
sion). Western blotting was done following standard protocols: protein
extracts from a deﬁned number of cells were separated in SDS–poly-
acrylamide gels, transferred to nitrocellulose membrane (Schleicher
und Schuell), and incubated with the respective antibodies. As primary
antibodies, a PML-speciﬁc polyclonal rabbit antiserum [18], an Ini1-
speciﬁc polyclonal rabbit antiserum [19], a Tpr-speciﬁc mouse mono-
clonal antibody (Oncogene Research), a Ku80-speciﬁc polyclonal
rabbit antiserum (Serotec), a HP1a-speciﬁc polyclonal rabbit antise-
rum (Upstate) or a a-tubulin-speciﬁc mouse monoclonal antibody
(Sigma) were applied overnight after blocking of the membrane in
5% dried-milk (in PBS). After incubation with the respective horserad-
ish peroxidase-coupled secondary antibody, the membrane was sub-
jected to enhanced chemiluminiscence immunodetection (Pierce).2.3. RNA interference
We selected small interfering RNAs (siRNAs) corresponding to a
conserved sequence (nucleotides 925–947; Accession No. U04847) to
target all published transcripts of the human hSNF5/INI1 gene (an-
nealed oligos GGAGAACUCACCAGAGAAGdTdT and CUUCU-
CUGGUGAGUUCUCCdTdT, Genset/Proligo). The conditions of
the RNA interference (RNAi) protocol were essentially as described
[20]. Brieﬂy, HeLa cells were seeded in 24-well dishes to reach a conﬂu-
ency of about 50% at the time of transfection. The next day, 3 ll of
Oligofectamine (Invitrogen) was mixed (per well) with 12 ll of Opti-
MEM medium (Gibco) and incubated for 5 min at room temperature
(RT). 3 ll of pre-annealed siRNAs (at a concentration of 20 lM) was
diluted in 50 ll of OptiMEM medium, mixed with the diluted Oligo-
fectamine and incubated for another 20 min. Before adding the mix-
ture to the cells (in 500 ll of DMEM without antibiotics per well), the
volume was adjusted to 100 ll to reach a ﬁnal concentration of 100 nM
RNA in the well. Forty-eight hours after transfection, protein levels
were examined by Western blot analysis and cells were infected and
subjected to immunoﬂuorescence where applicable.
2.4. Virus preparation and infection
The VSV-G pseudotyped particles were produced as previously de-
scribed [21] using pTRIP-LTR-EGFP as the genomic vector and the
infectious titer of the stocks was determined by limiting dilution anal-
ysis of transduced HeLa cells using the vector-encoded EGFP protein
as a marker. Cells were transduced by incubation with the concen-
trated virus stock in a small volume of medium at 37% for the indi-
cated time span.
2.5. Cell fractionation
To isolate nuclei, cells were resuspended (4 · 107 cells/ml) in buﬀer A
(10 mM HEPES [pH 7.9], 10 mM KCl, 1.5 mM MgCl2, 0.34 M su-
crose, 10% glycerol, 1 mM DTT, 5 lg of aprotinin/ml, 5 lg of leupep-
tin/ml, 0.5 g of pepstatin A/ml, and 0.1 mM phenylmethylsulfonyl
ﬂuoride). Triton X-100 was added (at 0.1% ﬁnal concentration) and
the cells were incubated for 5 min on ice. Nuclei were collected in
the pellet by low speed centrifugation (4 min, 1300 · g, 4 C) and
washed once in buﬀer A before resuspension in 1· sample buﬀer (2·
volume of supernatant). The supernatant fraction was diluted 1:1 in
2· sample buﬀer. The samples were boiled for 8 min and equal volumes
were loaded on the gel.
2.6. Annexin-V assay
Double staining for Annexin-V-Fluorescein and propidium iodide
(PI) was performed using the Annexin-V-FLUOS staining kit from
Roche according to the manufacturers instructions. Cells that stained
positive for PI (dead cells) were excluded from the analysis. Data were
acquired on a FACSCALIBUR cytometer and analyzed using Cell-
Quest software (both Becton–Dickinson, Pont de Claix, France).
2.7. Quantitative PCR
To avoid quantiﬁcation of unintegrated vector DNA, we prepared
genomic DNA from HeLa cells several weeks after infection [22,23] in
the presence or absence of Ini1 protein. Quantitative PCR (qPCR)
was carried out on an ABIPRISM 7000 sequence detection system
using SYBR green (both Applied Biosystems). All primers were
designed with the PrimerExpress 2.0 software (Applied Biosystems).
Primer pairs PP1 and PP2 are mapping within the provirus (5 0TGCT-
CTGGAAAACTCATTTGCA3 0 (PP1 forward) and 5 0CCAACT-
AGCATTCCAAGGCAC30 (PP1 reverse) as well as 5 0CCATTCG-
ATTAGTGAACGGATCT3 0 (PP2 forward) and 5 0TGCCATTTG-
TGAATTCGGC3 0 (PP2 reverse)). Primers amplifying b-actin (exonic)
were used as cellular reference for normalization (5 0TGTCCAC-
CTTCCAGCAGATGT30 (forward) and 5 0CGGACTCGTCATAC-
TCCTGCTT30 (reverse)). All experiments were performed in triplicate.3. Results and discussion
3.1. Cytoplasmic accumulation of PML after retroviral infection
is independent of Ini1
We initiated our studies by setting up a RNAi protocol to
speciﬁcally deplete Ini1. We selected siRNAs corresponding
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scripts of the human hSNF5/INI1 gene. Cellular Ini1 levels
were reproducibly and speciﬁcally decreased to undetectable
levels 48 h after transfection of Ini1 siRNAs (Fig. 1). This de-
gree of depletion lasted for about two days before endogenous
Ini1 levels rebounded to normal levels at days 5–6 (data not
shown). Importantly, the expression of several unrelated pro-
teins including PML was not aﬀected (Fig. 1). Moreover,
Ini1 expression levels remained unchanged after retroviral
infection (Fig. 1A) and after transfection of siRNAs targeting
unrelated proteins (Fig. 1B and unpublished data).
Next, we aimed to reproduce the cytoplasmic movement of
PML after retroviral infection. Immunoﬂuorescence analysis
of untreated HeLa cells using a PML-speciﬁc antiserum [18] re-
vealed the expected pattern of nuclear speckles in a slight nucle-
oplasmic background staining of soluble PML. Only rarely, we
detected a cytoplasmic accumulation of the protein in speckled
structures (Fig. 2A and B). We then employed VSV-G-pseudo-
typed, HIV-1-based TRIP-LTR-EGFP vector particles [24] to
investigate the eﬀect of retroviral infection on PML localiza-
tion. In sharp contrast to untreated cells, we observed a marked
increase in cytoplasmic PML staining accumulating in the
appearance of speckled structures in the cytoplasm of HeLa
cells, which had been exposed for 2 h to vector particles equiv-
alent to a MOI of 2.5 (Fig. 2A and B). Determination of the
number of nuclear vs. cytoplasmic dots in more than 200 ran-
domly chosen, morphologically intact cells from three indepen-
dent experiments revealed a roughly 10-fold increase in the
average number of cytoplasmic speckles per cell shortly after
retroviral infection (Fig. 2B). Dilution of the infection dose to
1/10th (m.o.i. of 0.25) resulted in a roughly 50% decrease in
the average number of cytoplasmic speckles, indicating a
dose-dependence (data not shown). This rapid response was
not accompanied by detectable changes in the total amount
of PML as shown by Western blot analysis (Fig. 1A) and hence
most likely reﬂects a signal-mediated reorganization of preex-
isting PML molecules in the cytoplasm. In agreement with pre-
vious reports [2,12,25], we could not observe a signiﬁcant
change in the average number or integrity of nuclear PML
bodies (Fig. 2B). It remained therefore formally possible that
the cytoplasmic speckles originated from PML molecules al-Fig. 1. Inﬂuence of RNAi and viral infection on cellular levels of
diﬀerent proteins. Western blot analysis 48 h after RNAi treatment on
cellular extracts (total protein of 4 · 104 cells/lane). Antibodies are
described in the main text. (A) PML and Ini1 levels are shown 48 h
after Ini1-speciﬁc (Ini1) or mock RNAi treatment () followed by 2 h
of retroviral (+) or mock-infection (), respectively. (B) Tpr, Ku80 and
Ini1 protein levels were detected 48 h after application of the dsRNAs
as indicated (RNAi): mock transfection (), Ini1-siRNAs or siRNAs
against the human Tpr protein.ready present in the cytoplasm [26]. To this end, we prepared
nuclear and cytoplasmatic extracts from cells exposed to vector
particles for 2 h along with mock-treated control cells and sub-
jected them toWestern blot analysis. The short exposure to ret-
roviral particles led to a signiﬁcant increase in the amount of
several PML isoforms in the cytoplasm barely detectable in un-
treated cells. This was accompanied by the simultaneous de-
crease in the nuclear fraction (Fig. 2E), while the total
amount of PML remained unchanged after infection (Fig.
1A). As expected, neither nuclear nor cytoplasmatic localiza-
tion of HP1-a or a-tubulin, respectively, were aﬀected by
short-term exposure to retroviral particles. Finally, no increase
in the proportion of apoptotic cells could be detected after
infection by Annexin-V staining (Fig. 2F). Since phosphatidyl-
serine translocation precedes oligo-nucleosomal DNA-frag-
mentation, after which nuclear membrane leakage occurs [27],
it is evident that early apoptotic events are not involved in
the nucleo-cytoplasmatic translocation of PML. In summary,
these results substantiate the observation that incoming HIV-
1 PICs trigger the accumulation of nuclear PML in speckled
cytoplasmic structures, as previously shown [2]. Since number
and integrity of nuclear PML bodies were not perturbed (Fig.
2B), it appears likely that the PML molecules accumulating
in the cytoplasm are recruited from soluble, nuclear pools.
We next applied our speciﬁc RNAi scheme to determine the
inﬂuence of transient Ini1 depletion on subcellular PML redis-
tribution upon retroviral infection. To this end, HeLa cells were
seeded in 6-well dishes containing small coverslips and sub-
jected to siRNA treatment the next day as described above.
After further culture for 48 h, cells were either mock infected
or exposed to pseudotyped HIV-1 particles for two hours at
37 C. Then, the coverslips were removed and the cells were
ﬁxed and stained (see above). In parallel, protein extracts were
prepared from the remaining cells in the wells in order to con-
trol for eﬃcient depletion of Ini1 by Western blot analysis. The
simultaneous examination of PML and Ini1 by immunoﬂuores-
cence was precluded since none of the a-Ini1 antibodies we
tested was functional in this assay. Similar to untreated cells,
PML was predominantly present in nuclear dots of cells either
mock transfected or treated with Ini1-speciﬁc siRNAs, the
accumulation of PML in speckled structures in the cytoplasm
being only occasionally detectable. Although this never reached
statistical signiﬁcance, the average number of nuclear PML
bodies was slightly increased in siRNA-treated cells compared
to untreated controls (compare Figs. 2B and D). This could
indicate an interferon-mediated response to the treatment of
cells with double-stranded RNA (dsRNA) [28]. PML has been
implicated in interferon-mediated processes and number and
size of PODs increase in response to interferon [10]. However,
neither the transfection procedure per se nor the cellular uptake
of small, dsRNA or the depletion of Ini1 profoundly inﬂuenced
the subcellular location of endogenous PML. Yet, upon short
exposure to VSV-G pseudotyped, HIV-based TRIP-LTR-
EGFP vector particles, a strong accumulation of speckled
PML structures occurred in the cytoplasm. Importantly, this
occurred irrespective of the presence of Ini1. Comparable to
what is observed in cells expressing normal Ini1 levels (Fig.
2B), an increase in the average number of cytoplasmic speckles
per cell from 0.7 (no infection) to 5.2 (after infection) accompa-
nied by a diﬀuse cytoplasmic staining following infection was
noted in Ini1-knock-down cells (Fig. 2D). This eﬀect was reli-
ably reproduced in several independent experiments (the slight
Fig. 2. Retroviral infection of HeLa cells induces the appearance of cytoplasmic PML foci irrespective of the presence of Ini1. (A) HeLa cells were
mock-infected (upper panel) or infected with pseudotyped retroviral particles (lower panel). Hoechst 33258 staining was done to deﬁne the nuclear
compartment (left panel, pseudocolored in red); Immunoﬂuorescence (PML-speciﬁc rabbit antibody (see text) and Cy3-coupled anti-rabbit
secondary antibody from Jackson Immuno Research Laboratories, pseudocolored in green) revealed intracellular distribution of PML protein
(middle panel). Merged images allow for the identiﬁcation of cytoplasmic speckles (see arrows). (B) The number of nuclear (deﬁned as colocalizing
with the DNA staining) and cytoplasmic PML speckles was determined for more than 200 randomly chosen, morphologically intact cells from three
independent experiments. Average values are indicated and standard deviations are represented by error bars. (C) HeLa cells were mock-infected
(upper panel) or infected (lower panel) on the day of apparent Ini1-depletion (see text). Hoechst 33258 staining and immunoﬂuorescence as in (B).
(D) Quantiﬁcation of the number of nuclear (as evidenced by colocalization with Hoechst 33258 staining) and cytoplasmic PML speckles was
determined for more than 200 randomly chosen, morphologically intact cells from three independent experiments. Average values are indicated and
standard deviations are represented by error bars. (E) Cellular fractionation of equal numbers of cells was performed 2 h after infection (+) or mock
infection () of Hela cells, to test for the pre- and postinfection subcellular distribution of PML and marker proteins in Western blot analysis. Purity
of the fractions (N=nuclear, C=cytoplasmic fraction) was conﬁrmed using a-HP1a (non-histone chromosomal protein, nuclear) and anti-a-tubulin
(microtubule component, cytoplasmic) staining. (F) FACS analysis of Annexin-V-Fluorescein/PI double-stained HeLa cells 2 h after infection (white
bar) or mock-infection (black bar). Indicated is the percentage of Annexin-V positive, PI-negative cells in the population. Error bars represent the
standard deviation from two independent experiments.
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siRNA treated versus control cells was statistically not signiﬁ-
cant, compare Fig. 2B and D). This further corroborated our
conclusion that Ini1 is dispensable for retrovirus-mediated
cytoplasmic accumulation of PML. Even if minute amounts
of Ini1, not detectable by our Western blot analysis, were pres-
ent in the cells after siRNA treatment, at least a notable reduc-
tion of the phenomenon would be expected. Recapitulating, we
conﬁrmed that the nuclear body constituent PML eﬃciently
accumulates in the cytoplasm in response to retroviral infec-
tion. Moreover, employing a RNAi-scheme for the transient
depletion of Ini1, we conclusively show that this phenomenon
occurs independently of Ini1. Consequently, the SWI/SNF
component Ini1 is not required for this process, which has been
suggested to be part of a cellular innate immune response to ret-
roviral infection.
3.2. Ini1 depletion does not inﬂuence integration eﬃciency
Although Ini1 is not aﬀecting PML de-localization, we
wanted to know whether it potentially aﬀects HIV-1 proviral
establishment via another pathway. To test for this possibility,
we determined the number of HeLa cells that were successfully
transduced with the EGFP-carrying vector in the presence or
absence of Ini1 using ﬂuorescence activated cell sorting
(FACS) analysis. As can be seen in Fig. 3, we did not observe
a signiﬁcant change in the transduction rate after knock-down
of Ini1. Irrespective of the presence of Ini1, comparable per-
centages of GFP positive cells were detected at the ﬁrst data
point analyzed (day two post transfection) and remained con-
stant for prolonged time of culture (more than 10 days; data
not shown). Therefore, it appears rather unlikely that integra-
tion in the absence of Ini1 was delayed during depletion and
occurred eﬃciently only after reappearance of Ini1, since Ini1
depletion lasted for 2–3 days after infection. Moreover, such
a scenario would require a stable, integration-competent viral
DNA form that is able to persist for at least two days. Yet, vir-
al DNA entering the nucleus either rapidly integrates or will be
circularized due to non-homologous DNA end joining mecha-
nisms, thus eliminating substrates for delayed integration
events [29]. A linear viral DNA implicated in pre-integration
latency can persist in the cytoplasm of resting CD4+ T cells
but has been shown to be rapidly degraded in dividing cellsFig. 3. Proviral establishment is not increased in cells devoid of Ini1.
(A) The percentage of EGFP-positive cells was determined by FACS
analysis after infection with a MOI of 0.6 of cells under mock- (mock)
or Ini1-knock-down (Ini1). Error bars represent the standard deviation
of 11 independent experiments. (B) qPCR analysis of DNA derived
from a representative experiment shown in (A). Results obtained with
two independent viral primer pairs (PP1 and PP2) are shown as fg viral
DNA/ng cellular DNA (determined with b-actin primers). Error bars
represent the standard deviation of triplicate experiments.as used in this study [30]. Altogether, we assume that a signif-
icant stimulatory eﬀect of Ini1 on integration could not have
been simply masked and that retroviral integration was not
merely delayed in Ini1-depleted cells.
To conﬁrm the FACS-based observation, we performed
qPCR analysis. We extracted DNA from cells that were in-
fected during Ini1- or mock knock-down after prolonged cul-
ture (more than three weeks) to avoid PCR-ampliﬁcation of
unintegrated viral DNA species [22,23]. Using two diﬀerent
primer pairs mapping within the TRIP-LTR-EGFP provirus
and b-actin as a cellular reference, we could clearly conﬁrm
that the number of successful integration events per cell (Fig.
3B) is not signiﬁcantly altered after Ini1 knock-down. Like-
wise, when transducing HeLa and MON cells (a tumor cell-line
showing bi-allelic deletion of the hSNF5/INI1 gene [31]) in
parallel, we could not detect an increased susceptibility of
the Ini1-deﬁcient MON cells towards infection using the same
approaches (data not shown).
Together, these results provide evidence that Ini1 is not cen-
tral to an early cellular antiretroviral response. Moreover, Ini1
apparently does not quantitatively stimulate HIV integration
in the context of viral infection, which contrasts the in vitro
ﬁnding of Ini1 stimulating the HIV-1 integration process
[15]. These observations should, however, not distract from a
possible implication of Ini1 in targeting HIV-1 to preferred
genomic sites or chromatin environments [15,16,32,33] with
potential consequences for both, eﬃcient viral replication
and establishment of latent reservoirs.
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